Registered Members Login:
   
Forgotten Your Details? Click Here To Recover +
Welcome To The ShareCafe Community - Talk Shares And Take Stock With Smart Investors - New Here? Click To Register >

A reminder to all members that you agree through the use of ShareCafe, that you understand and accept the TERMS OF USE.


2 Pages (Click to Jump) V   1 2 >   
 
  
Reply to this topic

RCE, RECCE PHARMACEUTICALS LTD
nipper
post Posted: Sep 8 2020, 01:30 PM
  Quote Post


Posts: 7,636
Thanks: 2575


https://www.afr.com/ . ..From the garage to a COVID-19 vaccine lab
QUOTE
When local synthetic antibiotics developer Recce Pharmaceuticals announced they had entered into an antiviral Sars CoV 2 screening program in partnership with the CSIRO and the University of Melbourne Doherty Institute back in July, the news threatened to overshadow some of the other pioneering work being undertaken by the health company.

The company is a potential world leader in something much larger in the long term: helping us combat our growing resistance to antibiotics.

Recce executive director, James Graham, says the company story is a classic Australian innovation story. It started in a retired chemist's garage and as he tinkered away he realised carpentry was not his thing so he picked up his test tubes again, Graham says.

The retired chemist was Johnson & Johnson former head of research, Graham Melrose, and what he was endeavouring to uncover was a synthetic compound that would overcome the superbugs now mutating as the world develops antibiotic resistance. Fast forward a few years and besides the SarsCoV2 partnership the company's executive director of regulatory affairs & microbiology, Michele Dilizia, will deliver the opening R&D Address at the World Anti Microbial Resistance (AMR) Congress next month outlining the case for further developing synthetic antibiotics.

Graham says Australia punches well above its weight in medical technology because we "think outside the square". Moreover, we have an extraordinarily valuable R&D rebate scheme in Australia where we get 43.5 per cent back on every $1 we spend. So if we spend $5 million on R&D applicable research, that is about $7 million of true cash runway. That incentivises us to stay local, to build local knowhow and advance the technology for intended sale in international markets, he says.

Yet staying in Australia does present some challenges because Australia accounts for only 3 per cent of the global antibiotic market whereas the US accounts for 48 per cent. It is for this reason many local players move offshore but Graham says the company is committed to having its manufacturing base here.

Furthermore, beside the partnership with the CSIRO and Doherty Institute, who have chosen the Recce compounds RECCE 327 and RECCE 529 as their priority one test candidate against coronavirus, the company is the only one in the world that has a qualified infectious disease designation awarded by the US Food and Drugs Administration for sepsis. This designation provides us 10 years of market exclusivity above and beyond a patent position. So that i's a government backed 10 year market exclusivity only from time of approval, Graham says. And while that is incredibly unique, we also have a pending human application for dosing on wounds in a West Australian hospital in a burns department led by a very prominent burn specialist.

For Graham, medical technology is just one of many potential winners for Australia that will transition the economy away from rocks and crops in the 21st century. Importantly, we are in a place that supports innovation and right now, we are an infectious disease company in the midst of a global infectious disease crisis. We could choose anywhere to be but there is nowhere we would rather want to be than Australia and we always will be here, Graham says.



--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne

Said 'Thanks' for this post: Farleap11  
 
macdtrader
post Posted: Jul 9 2020, 08:13 PM
  Quote Post


Posts: 137
Thanks: 10


In Reply To: nipper's post @ Jul 9 2020, 07:48 PM

Spectacular performer

 
nipper
post Posted: Jul 9 2020, 07:48 PM
  Quote Post


Posts: 7,636
Thanks: 2575


some boost in these Covid times. What it means is almost unimportant; they are throwing everything t the problem.
QUOTE
RECCE Compounds Selected by CSIRO/Doherty Institute in Priority 1 Candidate Group for SARS-CoV-2 Antiviral Screening Program
Highlights:

RECCE 327 and New RECCE 529 compounds were selected for their unique mechanism of actions against hyper-mutation, as indicated on bacteria and viruses (respectively)
Testing program will be conducted by CSIRO & University of Melbourne at the Doherty Institute
Therapeutic antiviral treatment focus of RECCE 327 and RECCE 529 may see added potential benefit against secondary bacterial infections

Priority 1 status is defined as highest or strong likelihood of antiviral or antiseptic efficacy Compounds in this grouping will be eligible for stage 1 laboratory screening trials.
and

QUOTE
Recce chairman John Prendergast said under the agreement, the company would retain all intellectual property rights. He added that Recce would fund the first stage of the program's development, which is expected to cost $35,000.

Dr Prendergast said if testing progresses, costs will increase at each stage.
The company will make (an) announcement in relation to progress to any further stage, and will detail any material associated costs. We are very pleased to have been selected by the CSIRO, one of the largest and most diverse scientific research organisations in the world, to investigate the efficacy of two of our promising compounds against SARS-CoV-2. The compounds' unique, universal mechanisms of action indicate the potential to attack a broad range of viruses and as well, overcome the threat of viruses' typical hyper-mutation into new and deadly pathogens.
It comes after CSIRO researchers last week found that lab-grown cells from the upper layer of the airway to the lungs the human bronchial epithelium reliably mimic a live person's airway's response to viruses. CSIRO research scientist Elizabeth Pharo said the airway model could potentially be used to screen up to 100 antiviral compounds within three months, and CSIRO is exploring ways to further accelerate screening including the use of robotic technology.
For many respiratory diseases, such as COVID-19, the airways act as the first responders to inhaled pathogens. When we infected our airway epithelial cultures with the 2009 pandemic H1N1 influenza virus, the cells had the same innate immune response as in a live person's airway. It is hoped this work will help improve our understanding of how COVID-19 may affect people with pre-existing lung conditions... said Dr Pharo

up 50% today to over $1.00. Was 30c a share in April



--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
nipper
post Posted: Nov 28 2019, 05:39 PM
  Quote Post


Posts: 7,636
Thanks: 2575


QUOTE
...ended the quarter with cash of $454,388 prior to the equity placement of $6,768,444 (before costs), post quarter end on 10 October 2019. On 18 September the business received further funds from the Australian Governmentunder the Australian R&D incentive scheme. The business is well funded to progress its commercial and clinical milestones.

Operational Highlights
We continue to receive good results from our manufacturing in preparation for pending human clinical studies. During the quarter we received a positive response from the US Food and Drug Administration relating to a five-fold increase in scaled manufacture of RECCE 327® and drug quality following submission of a Chemistry, Manufacturing and Controls (CMC) data pack as part of the investigational drug application process.

A leading international clinical trial logistics group was contracted to handle dispatch and delivery of RECCE® 327 globally, according to FDA requirements.

International Interest Growing – The Company was invited to give the opening R&D address at the World Antimicrobial Resistance Congress in the US on 7 November




--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
macdtrader
post Posted: Nov 6 2019, 08:38 PM
  Quote Post


Posts: 137
Thanks: 10


In Reply To: macdtrader's post @ Nov 5 2019, 01:21 PM

Behaving beautifully.
Limited supply. Low volume retrace into previous resistance at 28.5.
I don't imagine this will sit sub 30c for long. Perhaps hours. A few days at worst before launch.
FDA stamp? Pack your xmas stocking full.

 
macdtrader
post Posted: Nov 5 2019, 01:21 PM
  Quote Post


Posts: 137
Thanks: 10


In Reply To: strayinvestor's post @ Oct 28 2019, 10:49 PM

Starting to take shape.
Im john holmes on this.
FDA approval and this will multi bag imho.
That's what Im holding and praying for.
Could be a ripper xmas earner.

 

Featured Stock Stories





strayinvestor
post Posted: Oct 28 2019, 10:49 PM
  Quote Post


Posts: 2


In Reply To: macdtrader's post @ Oct 28 2019, 07:19 PM

The biggest uncertainty is that it is still pre clinical .

 
macdtrader
post Posted: Oct 28 2019, 07:19 PM
  Quote Post


Posts: 137
Thanks: 10


In Reply To: strayinvestor's post @ Oct 26 2019, 09:05 AM

That's a big positive but I want to hear some negatives on this stock.

 
strayinvestor
post Posted: Oct 26 2019, 09:05 AM
  Quote Post


Posts: 2


In Reply To: macdtrader's post @ Oct 25 2019, 10:43 PM

I like that it has FDA QIDP designation which gives the company fast track regulatory review plus 10 years of market exclusivity.

 
macdtrader
post Posted: Oct 25 2019, 10:43 PM
  Quote Post


Posts: 137
Thanks: 10


In Reply To: macdtrader's post @ Oct 25 2019, 09:08 PM

Recce also to give the opening address at the at 2019 World Antibiotic Resistance Congress.
600 attendees from 40 countries.
I've taken a small starter position with the intention to get heavy before the meeting.
I'm looking for feedback as to why I shouldn't.


 
 


2 Pages (Click to Jump) V   1 2 >

Back To Top Of Page
Reply to this topic


You agree through the use of ShareCafe, that you understand and accept the TERMS OF USE.


TERMS OF USE  -  CONTACT ADMIN  -  ADVERTISING